Eli Lilly (LLY): FY25 Q1 earnings call, May 1, 2025
No Kalshi or Polymarket word markets were listed for Eli Lilly’s May 1, 2025 earnings call (FY25 Q1). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
24 matches for “Zepbound”; 5 quoted, at least 25 words apart.
…Our key products defined as Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio and Zepbound grew by more than $4 billion and now account for $7.5 billion…
…in Q1, driven by strong volume growth of our key products, including Zepbound and Mounjaro, partially offset by a 7% decline in price. Moving to…
…the next few months. Finally, moving to Cardiometabolic Health, both Mounjaro and Zepbound posted a strong revenue growth. Mounjaro sales were $3.8 billion more than…
…diabetes and developing the ecosystem to treat obesity as a chronic disease. Zepbound performance was also robust, as sales increased by $1.8 billion to $2.3…
…higher dose Zepbound vials adding two additional doses for patients to access Zepbound through the self-pay channel. The uptake of Zepbound Vials has been strong…
Agents: this page as TSV at /api/v1/appearances/eli-lilly:2025-05-01:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2025-05-01:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP